https://www.businesswire.com/news/home/20260106659371/en/ZIIHERA-Plus-TEVIMBRA-and-Chemotherapy-A-Potential-New-Standard-for-First-Line-HER2-Advanced-GEA
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial e...
new standardziiheraplustevimbrachemotherapy